specifically to [a ligand] an antigen, wherein said [ligand] antigen is a protein on the surface of a cell or a viral protein;

a transmembrane domain; and

a cytoplasmic domain which ~~transduces~~ initiates a signal resulting in activation of a secondary messenger system, [said cytoplasmic domain selected from the group consisting of CD3 zeta, CD3 eta, CD3 gamma, CD3 delta, CD3 epsilon and the gamma chain of the F_c receptor,

wherein said extracellular domain and cytoplasmic are not naturally joined together,] and when said chimeric protein is expressed as a membrane bound protein in a selected mammalian host cell under conditions suitable for expression, said membrane bound protein initiates signalling [is] in said host cell when said extracellular domain binds to said [ligand] antigen.

Claim 59, first line, delete "80" and insert --57--.

64. (Amended) A mammalian cell comprising as a surface membrane protein, [a] the chimeric protein [according to] of Claim [79] 57.

Claim 65, first line, delete "A" (first occurrence) and insert --The--; and

delete "86" and insert--64--.

E3

67. (Amended) [A] The mammalian cell [comprising as a surface membrane protein, a protein according to] of Claim [82, wherein said cell] 64, which is a cytotoxic T lymphocyte.

E4

69. (Twice Amended) [A] The mammalian cell [comprising as a surface membrane protein, a protein according to] of Claim [85] 64 wherein said cell is substantially free of surface expression of at least one of Class I or Class II Major Histocompatibility Complex antigens.

Kindly add the following new claim 71.

E5

--71. A protein according to claim 57, wherein said cytoplasmic domain is selected from the group consisting of the CD3 zeta chain, the CD3 eta chain, the CD3 gamma chain, the CD3 delta chain, the CD3 epsilon chain, the gamma chain of F_c receptor and a tyrosine kinase.--

REMARKS

I. A substitute Declaration relating to co-inventor Irving will be filed shortly.